Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company will engage in a fireside chat on Tuesday, April 8, 2025, at 11:00 am EDT. The conference is scheduled to run from April 7-10, 2025. Interested parties can access the webcast through the 'Events' section of Arcutis' website, with the recording remaining available for 180 days after the conference.
Arcutis Biotherapeutics (Nasdaq: ARQT), un'azienda biofarmaceutica in fase commerciale specializzata in innovazioni nell'immuno-dermatologia, ha annunciato la sua partecipazione alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute.
L'azienda parteciperà a una chiacchierata informale il martedì 8 aprile 2025, alle 11:00 EDT. La conferenza si svolgerà dal 7 al 10 aprile 2025. Le parti interessate possono accedere al webcast tramite la sezione 'Eventi' del sito web di Arcutis, con la registrazione disponibile per 180 giorni dopo la conferenza.
Arcutis Biotherapeutics (Nasdaq: ARQT), una empresa biofarmacéutica en etapa comercial especializada en innovaciones en inmuno-dermatología, ha anunciado su participación en la 24ª Conferencia Virtual Anual de Needham sobre Salud.
La empresa participará en una charla informal el martes 8 de abril de 2025, a las 11:00 am EDT. La conferencia está programada del 7 al 10 de abril de 2025. Las partes interesadas pueden acceder a la transmisión en vivo a través de la sección 'Eventos' del sitio web de Arcutis, con la grabación disponible durante 180 días después de la conferencia.
Arcutis Biotherapeutics (Nasdaq: ARQT), 면역피부과 혁신을 전문으로 하는 상업 단계의 생명공학 회사가 제24회 니드햄 연례 가상 의료 회의에 참여한다고 발표했습니다.
회사는 2025년 4월 8일 화요일, 동부 표준시 기준 오전 11:00에 화상 대화에 참여할 예정입니다. 회의는 2025년 4월 7일부터 10일까지 진행됩니다. 관심 있는 분들은 Arcutis 웹사이트의 '이벤트' 섹션을 통해 웹캐스트에 접속할 수 있으며, 회의 후 180일 동안 녹화본을 이용할 수 있습니다.
Arcutis Biotherapeutics (Nasdaq: ARQT), une entreprise biopharmaceutique en phase commerciale spécialisée dans les innovations en immuno-dermatologie, a annoncé sa participation à la 24e Conférence Virtuelle Annuelle de Needham sur la Santé.
L'entreprise participera à une discussion informelle le mardi 8 avril 2025, à 11h00 EDT. La conférence est prévue du 7 au 10 avril 2025. Les parties intéressées peuvent accéder au webcast via la section 'Événements' du site Web d'Arcutis, l'enregistrement restant disponible pendant 180 jours après la conférence.
Arcutis Biotherapeutics (Nasdaq: ARQT), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf Innovationen in der Immun-Dermatologie spezialisiert hat, hat seine Teilnahme an der 24. jährlichen Needham virtuellen Gesundheitskonferenz angekündigt.
Das Unternehmen wird am Dienstag, den 8. April 2025, um 11:00 Uhr EDT an einem informellen Gespräch teilnehmen. Die Konferenz ist vom 7. bis 10. April 2025 geplant. Interessierte können über den Bereich 'Veranstaltungen' auf der Website von Arcutis auf den Webcast zugreifen, wobei die Aufzeichnung 180 Tage nach der Konferenz verfügbar bleibt.
- None.
- None.
WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 2025.
Details for the company’s participation are as follows:
Fireside Chat Date: Tuesday, April 8, 2025
Fireside Chat Time: 11:00 am EDT
The webcast for this conference may be accessed at the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Latha Vairavan, Vice President, Finance and Corporate Controller
ir@arcutis.com
FAQ
When is Arcutis (ARQT) presenting at the Needham Healthcare Conference 2025?
How long will the ARQT Needham Conference webcast be available for replay?
Where can investors access the ARQT Needham Conference presentation webcast?
What type of company is ARQT presenting at the Needham Healthcare Conference?
